To the part under naty, I just need to add the industry average to my part of operating management
Operating management (Nathalie)
This section analyzes the operating performance of Biogen compared to Johnson & Johnson. The Analysis will reveal how efficiently the company of interest (Biogen) is keeping its operating costs low while generating revenue compared to its major competitor. This efficiency is compared to that of its major competitor – Johson & Johnson. Four key financial ratios are used to evaluate this performance including Net Profit Margin, Gross Profit Margin, EBITDA, and Tax rate. The table below illustrates the above-stated ratio for the most current year – 2021.
Operating Management ratios
Biogen
Johnson & Johnson
Net Profit Margin
14.170
22.26
Gross Profit Margin
80.789
68.16
NOPAT (figure in thousands)
= NOPAT/ Net sales
For biogen: = 13.672
For JNJ: = 19.858

13.672
19.858
EBITDA Margin
36.039
32.42
Tax rate (based on income statement)
3.01
10.81

For this financial, it is evident from the table above that Biogen outperformed JNJ in three financial ratios including Gross profit margin, EBITA, and Tax rate. This implies that Biogen did better in maintaining the costs of sales low compared to JNJ which gave it a relatively high gross profit margin. However, compared to Biogen, JNJ had a better strategy for managing its expenses during the financial which gave it a significantly higher net profit margin. Both companies did well regarding their EBITDA (36.039 and 32.42 for Biogen and JNJ respectively) when benchmarked with the industry standard of 10% (Macrotrends, 2022). Even so, Biogen outperformed JNJ in this ratio. In terms of the effective tax rate, Biogen has a significantly lower value compared to JNJ which means that it has better tax reduction policies in place including effectively utilizing tax deductions and credits, compared to its major competitor.